nodes	percent_of_prediction	percent_of_DWPC	metapath
Dinoprostone—ABCC5—Zidovudine—acquired immunodeficiency syndrome	0.0647	0.0895	CbGbCtD
Dinoprostone—CYP11A1—Saquinavir—acquired immunodeficiency syndrome	0.0638	0.0884	CbGbCtD
Dinoprostone—SLC22A6—Stavudine—acquired immunodeficiency syndrome	0.034	0.047	CbGbCtD
Dinoprostone—SLC22A11—Zidovudine—acquired immunodeficiency syndrome	0.0334	0.0462	CbGbCtD
Dinoprostone—SLC22A7—Zidovudine—acquired immunodeficiency syndrome	0.0318	0.044	CbGbCtD
Dinoprostone—ABCC4—Zidovudine—acquired immunodeficiency syndrome	0.0311	0.043	CbGbCtD
Dinoprostone—SLCO1A2—Indinavir—acquired immunodeficiency syndrome	0.0265	0.0367	CbGbCtD
Dinoprostone—SLC22A6—Didanosine—acquired immunodeficiency syndrome	0.0258	0.0356	CbGbCtD
Dinoprostone—SLCO1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0257	0.0356	CbGbCtD
Dinoprostone—SLCO1B1—Indinavir—acquired immunodeficiency syndrome	0.025	0.0346	CbGbCtD
Dinoprostone—SLCO1B1—Nelfinavir—acquired immunodeficiency syndrome	0.0243	0.0336	CbGbCtD
Dinoprostone—ABCC4—Lamivudine—acquired immunodeficiency syndrome	0.024	0.0333	CbGbCtD
Dinoprostone—SLC22A1—Indinavir—acquired immunodeficiency syndrome	0.0234	0.0323	CbGbCtD
Dinoprostone—SLCO1A2—Saquinavir—acquired immunodeficiency syndrome	0.0233	0.0322	CbGbCtD
Dinoprostone—SLCO1A2—Ritonavir—acquired immunodeficiency syndrome	0.0233	0.0322	CbGbCtD
Dinoprostone—SLC22A1—Nelfinavir—acquired immunodeficiency syndrome	0.0227	0.0314	CbGbCtD
Dinoprostone—SLC22A2—Zidovudine—acquired immunodeficiency syndrome	0.0226	0.0313	CbGbCtD
Dinoprostone—SLCO1B1—Saquinavir—acquired immunodeficiency syndrome	0.0219	0.0304	CbGbCtD
Dinoprostone—SLCO1B1—Ritonavir—acquired immunodeficiency syndrome	0.0219	0.0304	CbGbCtD
Dinoprostone—SLC22A1—Saquinavir—acquired immunodeficiency syndrome	0.0205	0.0284	CbGbCtD
Dinoprostone—SLC22A8—Zidovudine—acquired immunodeficiency syndrome	0.0194	0.0269	CbGbCtD
Dinoprostone—SLC22A2—Lamivudine—acquired immunodeficiency syndrome	0.0175	0.0242	CbGbCtD
Dinoprostone—SLC22A1—Lamivudine—acquired immunodeficiency syndrome	0.0152	0.0211	CbGbCtD
Dinoprostone—SLC22A6—Zidovudine—acquired immunodeficiency syndrome	0.0135	0.0187	CbGbCtD
Dinoprostone—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0112	0.0154	CbGbCtD
Dinoprostone—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0105	0.0145	CbGbCtD
Dinoprostone—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0105	0.0145	CbGbCtD
Dinoprostone—SLC22A6—Lamivudine—acquired immunodeficiency syndrome	0.0105	0.0145	CbGbCtD
Dinoprostone—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.00949	0.0131	CbGbCtD
Dinoprostone—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.00795	0.011	CbGbCtD
Dinoprostone—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00719	0.00995	CbGbCtD
Dinoprostone—CYP19A1—semen—acquired immunodeficiency syndrome	0.00255	0.0311	CbGeAlD
Dinoprostone—HPGDS—blood plasma—acquired immunodeficiency syndrome	0.00203	0.0248	CbGeAlD
Dinoprostone—PTGIR—endothelium—acquired immunodeficiency syndrome	0.00186	0.0227	CbGeAlD
Dinoprostone—PTGIR—blood plasma—acquired immunodeficiency syndrome	0.00165	0.0202	CbGeAlD
Dinoprostone—SLC51B—digestive system—acquired immunodeficiency syndrome	0.00146	0.0178	CbGeAlD
Dinoprostone—SLC51B—lung—acquired immunodeficiency syndrome	0.00122	0.0149	CbGeAlD
Dinoprostone—SLCO1B1—blood plasma—acquired immunodeficiency syndrome	0.00117	0.0143	CbGeAlD
Dinoprostone—PTGER4—lymphoid tissue—acquired immunodeficiency syndrome	0.00108	0.0132	CbGeAlD
Dinoprostone—PTGER4—digestive system—acquired immunodeficiency syndrome	0.00107	0.013	CbGeAlD
Dinoprostone—SLC51A—digestive system—acquired immunodeficiency syndrome	0.00105	0.0128	CbGeAlD
Dinoprostone—PTGER2—blood—acquired immunodeficiency syndrome	0.00103	0.0126	CbGeAlD
Dinoprostone—PTGER4—blood—acquired immunodeficiency syndrome	0.00101	0.0124	CbGeAlD
Dinoprostone—PTGER2—bone marrow—acquired immunodeficiency syndrome	0.001	0.0122	CbGeAlD
Dinoprostone—SLC51A—blood—acquired immunodeficiency syndrome	0.000997	0.0122	CbGeAlD
Dinoprostone—PTGER2—vagina—acquired immunodeficiency syndrome	0.000959	0.0117	CbGeAlD
Dinoprostone—SLC51A—vagina—acquired immunodeficiency syndrome	0.000924	0.0113	CbGeAlD
Dinoprostone—ABCC4—blood plasma—acquired immunodeficiency syndrome	0.000916	0.0112	CbGeAlD
Dinoprostone—PTGER2—lung—acquired immunodeficiency syndrome	0.000907	0.0111	CbGeAlD
Dinoprostone—PTGER3—digestive system—acquired immunodeficiency syndrome	0.000902	0.011	CbGeAlD
Dinoprostone—PTGER4—lung—acquired immunodeficiency syndrome	0.00089	0.0109	CbGeAlD
Dinoprostone—SLC51A—lung—acquired immunodeficiency syndrome	0.000874	0.0107	CbGeAlD
Dinoprostone—PTGER4—nervous system—acquired immunodeficiency syndrome	0.000824	0.0101	CbGeAlD
Dinoprostone—SLC51A—nervous system—acquired immunodeficiency syndrome	0.000809	0.00988	CbGeAlD
Dinoprostone—SLCO3A1—retina—acquired immunodeficiency syndrome	0.000799	0.00976	CbGeAlD
Dinoprostone—PTGER1—nervous system—acquired immunodeficiency syndrome	0.000796	0.00972	CbGeAlD
Dinoprostone—PTGER4—central nervous system—acquired immunodeficiency syndrome	0.000793	0.00969	CbGeAlD
Dinoprostone—HPGDS—lymphoid tissue—acquired immunodeficiency syndrome	0.000789	0.00964	CbGeAlD
Dinoprostone—HPGDS—digestive system—acquired immunodeficiency syndrome	0.00078	0.00952	CbGeAlD
Dinoprostone—SLC51A—central nervous system—acquired immunodeficiency syndrome	0.000779	0.00952	CbGeAlD
Dinoprostone—PTGER1—central nervous system—acquired immunodeficiency syndrome	0.000766	0.00936	CbGeAlD
Dinoprostone—PTGER3—lung—acquired immunodeficiency syndrome	0.000754	0.0092	CbGeAlD
Dinoprostone—HPGDS—blood—acquired immunodeficiency syndrome	0.000743	0.00907	CbGeAlD
Dinoprostone—SLCO4A1—retina—acquired immunodeficiency syndrome	0.000728	0.00889	CbGeAlD
Dinoprostone—ABCC5—retina—acquired immunodeficiency syndrome	0.000724	0.00884	CbGeAlD
Dinoprostone—HPGDS—bone marrow—acquired immunodeficiency syndrome	0.000719	0.00878	CbGeAlD
Dinoprostone—HPGDS—spinal cord—acquired immunodeficiency syndrome	0.000716	0.00874	CbGeAlD
Dinoprostone—PTGER3—nervous system—acquired immunodeficiency syndrome	0.000698	0.00852	CbGeAlD
Dinoprostone—SLCO2A1—skin of body—acquired immunodeficiency syndrome	0.000695	0.00848	CbGeAlD
Dinoprostone—HPGDS—vagina—acquired immunodeficiency syndrome	0.000689	0.00841	CbGeAlD
Dinoprostone—PTGER3—central nervous system—acquired immunodeficiency syndrome	0.000672	0.0082	CbGeAlD
Dinoprostone—HPGDS—lung—acquired immunodeficiency syndrome	0.000651	0.00795	CbGeAlD
Dinoprostone—PTGIR—digestive system—acquired immunodeficiency syndrome	0.000636	0.00776	CbGeAlD
Dinoprostone—PTGER4—brain—acquired immunodeficiency syndrome	0.00063	0.00769	CbGeAlD
Dinoprostone—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000622	0.0076	CbGeAlD
Dinoprostone—PTGER2—lymph node—acquired immunodeficiency syndrome	0.00062	0.00757	CbGeAlD
Dinoprostone—SLC22A11—digestive system—acquired immunodeficiency syndrome	0.000619	0.00756	CbGeAlD
Dinoprostone—SLC51A—brain—acquired immunodeficiency syndrome	0.000619	0.00755	CbGeAlD
Dinoprostone—PTGER4—lymph node—acquired immunodeficiency syndrome	0.000609	0.00743	CbGeAlD
Dinoprostone—PTGIR—blood—acquired immunodeficiency syndrome	0.000606	0.00739	CbGeAlD
Dinoprostone—SLC22A7—digestive system—acquired immunodeficiency syndrome	0.000605	0.00738	CbGeAlD
Dinoprostone—HPGDS—nervous system—acquired immunodeficiency syndrome	0.000603	0.00736	CbGeAlD
Dinoprostone—PTGFR—lung—acquired immunodeficiency syndrome	0.000602	0.00736	CbGeAlD
Dinoprostone—SLC51A—lymph node—acquired immunodeficiency syndrome	0.000598	0.0073	CbGeAlD
Dinoprostone—SLCO1C1—spinal cord—acquired immunodeficiency syndrome	0.000585	0.00715	CbGeAlD
Dinoprostone—PTGIR—spinal cord—acquired immunodeficiency syndrome	0.000583	0.00712	CbGeAlD
Dinoprostone—HPGDS—central nervous system—acquired immunodeficiency syndrome	0.000581	0.00709	CbGeAlD
Dinoprostone—SLC22A2—digestive system—acquired immunodeficiency syndrome	0.000538	0.00657	CbGeAlD
Dinoprostone—SLCO3A1—blood—acquired immunodeficiency syndrome	0.000534	0.00653	CbGeAlD
Dinoprostone—PTGER3—brain—acquired immunodeficiency syndrome	0.000533	0.00651	CbGeAlD
Dinoprostone—PTGIR—lung—acquired immunodeficiency syndrome	0.000531	0.00648	CbGeAlD
Dinoprostone—CYP11A1—blood—acquired immunodeficiency syndrome	0.000524	0.0064	CbGeAlD
Dinoprostone—PTGER3—lymph node—acquired immunodeficiency syndrome	0.000515	0.00629	CbGeAlD
Dinoprostone—SLCO3A1—spinal cord—acquired immunodeficiency syndrome	0.000515	0.00629	CbGeAlD
Dinoprostone—SLCO4A1—digestive system—acquired immunodeficiency syndrome	0.000511	0.00624	CbGeAlD
Dinoprostone—SLCO3A1—vagina—acquired immunodeficiency syndrome	0.000495	0.00605	CbGeAlD
Dinoprostone—SLCO1C1—nervous system—acquired immunodeficiency syndrome	0.000493	0.00602	CbGeAlD
Dinoprostone—PTGIR—nervous system—acquired immunodeficiency syndrome	0.000492	0.006	CbGeAlD
Dinoprostone—SLCO2A1—vagina—acquired immunodeficiency syndrome	0.000491	0.00599	CbGeAlD
Dinoprostone—SLCO1C1—central nervous system—acquired immunodeficiency syndrome	0.000475	0.0058	CbGeAlD
Dinoprostone—PTGIR—central nervous system—acquired immunodeficiency syndrome	0.000473	0.00578	CbGeAlD
Dinoprostone—SLCO4A1—spinal cord—acquired immunodeficiency syndrome	0.000469	0.00573	CbGeAlD
Dinoprostone—SLCO3A1—lung—acquired immunodeficiency syndrome	0.000469	0.00572	CbGeAlD
Dinoprostone—ABCC5—bone marrow—acquired immunodeficiency syndrome	0.000468	0.00572	CbGeAlD
Dinoprostone—SLCO2A1—lung—acquired immunodeficiency syndrome	0.000464	0.00567	CbGeAlD
Dinoprostone—HPGDS—brain—acquired immunodeficiency syndrome	0.000461	0.00563	CbGeAlD
Dinoprostone—SLCO4A1—vagina—acquired immunodeficiency syndrome	0.000451	0.00551	CbGeAlD
Dinoprostone—SLCO1B1—digestive system—acquired immunodeficiency syndrome	0.00045	0.00549	CbGeAlD
Dinoprostone—ABCC5—vagina—acquired immunodeficiency syndrome	0.000449	0.00548	CbGeAlD
Dinoprostone—HPGDS—lymph node—acquired immunodeficiency syndrome	0.000445	0.00544	CbGeAlD
Dinoprostone—SLCO3A1—nervous system—acquired immunodeficiency syndrome	0.000434	0.0053	CbGeAlD
Dinoprostone—SLCO2A1—nervous system—acquired immunodeficiency syndrome	0.00043	0.00525	CbGeAlD
Dinoprostone—SLCO1B1—blood—acquired immunodeficiency syndrome	0.000428	0.00523	CbGeAlD
Dinoprostone—SLCO4A1—lung—acquired immunodeficiency syndrome	0.000427	0.00521	CbGeAlD
Dinoprostone—CYP11A1—nervous system—acquired immunodeficiency syndrome	0.000425	0.00519	CbGeAlD
Dinoprostone—ABCC5—lung—acquired immunodeficiency syndrome	0.000424	0.00518	CbGeAlD
Dinoprostone—SLCO3A1—central nervous system—acquired immunodeficiency syndrome	0.000418	0.0051	CbGeAlD
Dinoprostone—SLCO2A1—central nervous system—acquired immunodeficiency syndrome	0.000414	0.00505	CbGeAlD
Dinoprostone—PTGFR—lymph node—acquired immunodeficiency syndrome	0.000412	0.00503	CbGeAlD
Dinoprostone—CYP11A1—central nervous system—acquired immunodeficiency syndrome	0.000409	0.005	CbGeAlD
Dinoprostone—SLCO2B1—digestive system—acquired immunodeficiency syndrome	0.000398	0.00486	CbGeAlD
Dinoprostone—SLCO4A1—nervous system—acquired immunodeficiency syndrome	0.000395	0.00483	CbGeAlD
Dinoprostone—SLCO4A1—central nervous system—acquired immunodeficiency syndrome	0.000381	0.00465	CbGeAlD
Dinoprostone—SLCO1C1—brain—acquired immunodeficiency syndrome	0.000377	0.0046	CbGeAlD
Dinoprostone—PTGIR—brain—acquired immunodeficiency syndrome	0.000376	0.00459	CbGeAlD
Dinoprostone—SLCO1A2—digestive system—acquired immunodeficiency syndrome	0.000366	0.00447	CbGeAlD
Dinoprostone—SLCO2B1—spinal cord—acquired immunodeficiency syndrome	0.000365	0.00446	CbGeAlD
Dinoprostone—SLCO1C1—lymph node—acquired immunodeficiency syndrome	0.000364	0.00445	CbGeAlD
Dinoprostone—PTGIR—lymph node—acquired immunodeficiency syndrome	0.000363	0.00443	CbGeAlD
Dinoprostone—SLC22A1—blood—acquired immunodeficiency syndrome	0.000362	0.00442	CbGeAlD
Dinoprostone—SLC22A7—brain—acquired immunodeficiency syndrome	0.000357	0.00436	CbGeAlD
Dinoprostone—ABCC4—digestive system—acquired immunodeficiency syndrome	0.000352	0.0043	CbGeAlD
Dinoprostone—SLC22A6—brain—acquired immunodeficiency syndrome	0.000345	0.00421	CbGeAlD
Dinoprostone—CYP19A1—blood—acquired immunodeficiency syndrome	0.00034	0.00416	CbGeAlD
Dinoprostone—SLCO1A2—spinal cord—acquired immunodeficiency syndrome	0.000336	0.0041	CbGeAlD
Dinoprostone—SLC22A1—vagina—acquired immunodeficiency syndrome	0.000336	0.0041	CbGeAlD
Dinoprostone—ABCC4—blood—acquired immunodeficiency syndrome	0.000336	0.0041	CbGeAlD
Dinoprostone—SLC22A8—blood—acquired immunodeficiency syndrome	0.000333	0.00407	CbGeAlD
Dinoprostone—SLCO2B1—lung—acquired immunodeficiency syndrome	0.000332	0.00406	CbGeAlD
Dinoprostone—SLCO3A1—brain—acquired immunodeficiency syndrome	0.000332	0.00405	CbGeAlD
Dinoprostone—SLCO2A1—brain—acquired immunodeficiency syndrome	0.000328	0.00401	CbGeAlD
Dinoprostone—CYP11A1—brain—acquired immunodeficiency syndrome	0.000325	0.00397	CbGeAlD
Dinoprostone—ABCC4—bone marrow—acquired immunodeficiency syndrome	0.000325	0.00396	CbGeAlD
Dinoprostone—SLCO3A1—lymph node—acquired immunodeficiency syndrome	0.00032	0.00391	CbGeAlD
Dinoprostone—SLCO2A1—lymph node—acquired immunodeficiency syndrome	0.000317	0.00388	CbGeAlD
Dinoprostone—CYP11A1—lymph node—acquired immunodeficiency syndrome	0.000314	0.00383	CbGeAlD
Dinoprostone—SLCO2B1—nervous system—acquired immunodeficiency syndrome	0.000308	0.00376	CbGeAlD
Dinoprostone—SLCO1A2—lung—acquired immunodeficiency syndrome	0.000306	0.00373	CbGeAlD
Dinoprostone—SLCO4A1—brain—acquired immunodeficiency syndrome	0.000302	0.00369	CbGeAlD
Dinoprostone—ABCC5—brain—acquired immunodeficiency syndrome	0.0003	0.00367	CbGeAlD
Dinoprostone—SLCO2B1—central nervous system—acquired immunodeficiency syndrome	0.000296	0.00362	CbGeAlD
Dinoprostone—ABCC4—lung—acquired immunodeficiency syndrome	0.000294	0.00359	CbGeAlD
Dinoprostone—SLC22A1—nervous system—acquired immunodeficiency syndrome	0.000294	0.00359	CbGeAlD
Dinoprostone—SLCO4A1—lymph node—acquired immunodeficiency syndrome	0.000292	0.00356	CbGeAlD
Dinoprostone—ABCC5—lymph node—acquired immunodeficiency syndrome	0.00029	0.00354	CbGeAlD
Dinoprostone—SLCO1A2—nervous system—acquired immunodeficiency syndrome	0.000283	0.00346	CbGeAlD
Dinoprostone—SLC22A1—central nervous system—acquired immunodeficiency syndrome	0.000283	0.00346	CbGeAlD
Dinoprostone—CYP19A1—nervous system—acquired immunodeficiency syndrome	0.000276	0.00337	CbGeAlD
Dinoprostone—SLCO1A2—central nervous system—acquired immunodeficiency syndrome	0.000273	0.00333	CbGeAlD
Dinoprostone—ABCC4—nervous system—acquired immunodeficiency syndrome	0.000272	0.00333	CbGeAlD
Dinoprostone—SLC22A8—nervous system—acquired immunodeficiency syndrome	0.00027	0.0033	CbGeAlD
Dinoprostone—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.000269	0.00188	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Nevirapine—acquired immunodeficiency syndrome	0.000268	0.00188	CcSEcCtD
Dinoprostone—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.000267	0.00187	CcSEcCtD
Dinoprostone—Chest pain—Indinavir—acquired immunodeficiency syndrome	0.000267	0.00187	CcSEcCtD
Dinoprostone—Myalgia—Indinavir—acquired immunodeficiency syndrome	0.000267	0.00187	CcSEcCtD
Dinoprostone—Arthralgia—Indinavir—acquired immunodeficiency syndrome	0.000267	0.00187	CcSEcCtD
Dinoprostone—Pain—Abacavir—acquired immunodeficiency syndrome	0.000267	0.00187	CcSEcCtD
Dinoprostone—Hyperhidrosis—Zidovudine—acquired immunodeficiency syndrome	0.000266	0.00186	CcSEcCtD
Dinoprostone—CYP19A1—central nervous system—acquired immunodeficiency syndrome	0.000266	0.00325	CbGeAlD
Dinoprostone—Syncope—Efavirenz—acquired immunodeficiency syndrome	0.000266	0.00186	CcSEcCtD
Dinoprostone—Tremor—Delavirdine—acquired immunodeficiency syndrome	0.000266	0.00186	CcSEcCtD
Dinoprostone—Angiopathy—Saquinavir—acquired immunodeficiency syndrome	0.000263	0.00184	CcSEcCtD
Dinoprostone—ABCC4—central nervous system—acquired immunodeficiency syndrome	0.000262	0.0032	CbGeAlD
Dinoprostone—Immune system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000262	0.00183	CcSEcCtD
Dinoprostone—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000262	0.00183	CcSEcCtD
Dinoprostone—Loss of consciousness—Efavirenz—acquired immunodeficiency syndrome	0.00026	0.00182	CcSEcCtD
Dinoprostone—SLC22A8—central nervous system—acquired immunodeficiency syndrome	0.00026	0.00318	CbGeAlD
Dinoprostone—Chills—Saquinavir—acquired immunodeficiency syndrome	0.00026	0.00182	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00026	0.00182	CcSEcCtD
Dinoprostone—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000259	0.00182	CcSEcCtD
Dinoprostone—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000259	0.00182	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.000259	0.00181	CcSEcCtD
Dinoprostone—Cough—Efavirenz—acquired immunodeficiency syndrome	0.000259	0.00181	CcSEcCtD
Dinoprostone—Tension—Ritonavir—acquired immunodeficiency syndrome	0.000257	0.0018	CcSEcCtD
Dinoprostone—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.000256	0.00179	CcSEcCtD
Dinoprostone—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.000256	0.00179	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.000255	0.00179	CcSEcCtD
Dinoprostone—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000254	0.00178	CcSEcCtD
Dinoprostone—Syncope—Delavirdine—acquired immunodeficiency syndrome	0.000254	0.00178	CcSEcCtD
Dinoprostone—Back pain—Ritonavir—acquired immunodeficiency syndrome	0.000254	0.00178	CcSEcCtD
Dinoprostone—Chest pain—Efavirenz—acquired immunodeficiency syndrome	0.000252	0.00177	CcSEcCtD
Dinoprostone—Arthralgia—Efavirenz—acquired immunodeficiency syndrome	0.000252	0.00177	CcSEcCtD
Dinoprostone—Myalgia—Efavirenz—acquired immunodeficiency syndrome	0.000252	0.00177	CcSEcCtD
Dinoprostone—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000252	0.00177	CcSEcCtD
Dinoprostone—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.000252	0.00177	CcSEcCtD
Dinoprostone—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000252	0.00177	CcSEcCtD
Dinoprostone—Shock—Indinavir—acquired immunodeficiency syndrome	0.000252	0.00176	CcSEcCtD
Dinoprostone—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000251	0.00176	CcSEcCtD
Dinoprostone—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000251	0.00176	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000251	0.00176	CcSEcCtD
Dinoprostone—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000251	0.00176	CcSEcCtD
Dinoprostone—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.00025	0.00175	CcSEcCtD
Dinoprostone—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.00025	0.00175	CcSEcCtD
Dinoprostone—Immune system disorder—Lamivudine—acquired immunodeficiency syndrome	0.00025	0.00175	CcSEcCtD
Dinoprostone—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000249	0.00175	CcSEcCtD
Dinoprostone—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	0.000249	0.00175	CcSEcCtD
Dinoprostone—Chills—Lamivudine—acquired immunodeficiency syndrome	0.000248	0.00174	CcSEcCtD
Dinoprostone—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.000247	0.00173	CcSEcCtD
Dinoprostone—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000247	0.00173	CcSEcCtD
Dinoprostone—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.000247	0.00173	CcSEcCtD
Dinoprostone—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.000247	0.00173	CcSEcCtD
Dinoprostone—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000247	0.00173	CcSEcCtD
Dinoprostone—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000247	0.00173	CcSEcCtD
Dinoprostone—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000246	0.00172	CcSEcCtD
Dinoprostone—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000245	0.00172	CcSEcCtD
Dinoprostone—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000245	0.00171	CcSEcCtD
Dinoprostone—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000244	0.00171	CcSEcCtD
Dinoprostone—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000243	0.0017	CcSEcCtD
Dinoprostone—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000242	0.00169	CcSEcCtD
Dinoprostone—Myalgia—Delavirdine—acquired immunodeficiency syndrome	0.000241	0.00169	CcSEcCtD
Dinoprostone—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000241	0.00169	CcSEcCtD
Dinoprostone—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.000241	0.00169	CcSEcCtD
Dinoprostone—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000239	0.00292	CbGeAlD
Dinoprostone—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000238	0.00167	CcSEcCtD
Dinoprostone—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000238	0.00166	CcSEcCtD
Dinoprostone—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000236	0.00166	CcSEcCtD
Dinoprostone—Tension—Lamivudine—acquired immunodeficiency syndrome	0.000236	0.00166	CcSEcCtD
Dinoprostone—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000236	0.00165	CcSEcCtD
Dinoprostone—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000235	0.00165	CcSEcCtD
Dinoprostone—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000235	0.00165	CcSEcCtD
Dinoprostone—SLCO2B1—brain—acquired immunodeficiency syndrome	0.000235	0.00287	CbGeAlD
Dinoprostone—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000235	0.00165	CcSEcCtD
Dinoprostone—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000234	0.00164	CcSEcCtD
Dinoprostone—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000234	0.00164	CcSEcCtD
Dinoprostone—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000233	0.00163	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000233	0.00163	CcSEcCtD
Dinoprostone—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000233	0.00163	CcSEcCtD
Dinoprostone—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000232	0.00162	CcSEcCtD
Dinoprostone—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000231	0.00162	CcSEcCtD
Dinoprostone—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.00023	0.00161	CcSEcCtD
Dinoprostone—Rash—Didanosine—acquired immunodeficiency syndrome	0.00023	0.00161	CcSEcCtD
Dinoprostone—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.00023	0.00161	CcSEcCtD
Dinoprostone—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00023	0.00161	CcSEcCtD
Dinoprostone—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00023	0.00161	CcSEcCtD
Dinoprostone—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000229	0.0016	CcSEcCtD
Dinoprostone—Headache—Didanosine—acquired immunodeficiency syndrome	0.000228	0.0016	CcSEcCtD
Dinoprostone—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000228	0.0016	CcSEcCtD
Dinoprostone—CYP1A2—blood—acquired immunodeficiency syndrome	0.000228	0.00278	CbGeAlD
Dinoprostone—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000228	0.0016	CcSEcCtD
Dinoprostone—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000228	0.00159	CcSEcCtD
Dinoprostone—SLCO2B1—lymph node—acquired immunodeficiency syndrome	0.000227	0.00277	CbGeAlD
Dinoprostone—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000227	0.00159	CcSEcCtD
Dinoprostone—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000226	0.00159	CcSEcCtD
Dinoprostone—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000226	0.00159	CcSEcCtD
Dinoprostone—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000226	0.00158	CcSEcCtD
Dinoprostone—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000225	0.00158	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000225	0.00158	CcSEcCtD
Dinoprostone—SLC22A1—brain—acquired immunodeficiency syndrome	0.000225	0.00274	CbGeAlD
Dinoprostone—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000224	0.00157	CcSEcCtD
Dinoprostone—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000224	0.00157	CcSEcCtD
Dinoprostone—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000224	0.00157	CcSEcCtD
Dinoprostone—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000223	0.00156	CcSEcCtD
Dinoprostone—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000223	0.00156	CcSEcCtD
Dinoprostone—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000223	0.00156	CcSEcCtD
Dinoprostone—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000222	0.00155	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.00022	0.00154	CcSEcCtD
Dinoprostone—Cough—Saquinavir—acquired immunodeficiency syndrome	0.00022	0.00154	CcSEcCtD
Dinoprostone—Pain—Indinavir—acquired immunodeficiency syndrome	0.000219	0.00153	CcSEcCtD
Dinoprostone—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000218	0.00153	CcSEcCtD
Dinoprostone—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000218	0.00152	CcSEcCtD
Dinoprostone—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000218	0.00152	CcSEcCtD
Dinoprostone—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000217	0.00152	CcSEcCtD
Dinoprostone—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000217	0.00152	CcSEcCtD
Dinoprostone—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000217	0.00152	CcSEcCtD
Dinoprostone—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000217	0.00152	CcSEcCtD
Dinoprostone—SLCO1A2—brain—acquired immunodeficiency syndrome	0.000216	0.00264	CbGeAlD
Dinoprostone—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000216	0.00151	CcSEcCtD
Dinoprostone—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000216	0.00151	CcSEcCtD
Dinoprostone—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000216	0.00151	CcSEcCtD
Dinoprostone—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000215	0.00151	CcSEcCtD
Dinoprostone—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000215	0.00151	CcSEcCtD
Dinoprostone—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000215	0.00151	CcSEcCtD
Dinoprostone—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000213	0.0015	CcSEcCtD
Dinoprostone—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000212	0.00148	CcSEcCtD
Dinoprostone—CYP19A1—brain—acquired immunodeficiency syndrome	0.000211	0.00258	CbGeAlD
Dinoprostone—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000211	0.00148	CcSEcCtD
Dinoprostone—Shock—Ritonavir—acquired immunodeficiency syndrome	0.00021	0.00147	CcSEcCtD
Dinoprostone—Cough—Lamivudine—acquired immunodeficiency syndrome	0.00021	0.00147	CcSEcCtD
Dinoprostone—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00021	0.00147	CcSEcCtD
Dinoprostone—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000209	0.00147	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000209	0.00147	CcSEcCtD
Dinoprostone—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000209	0.00146	CcSEcCtD
Dinoprostone—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000208	0.00146	CcSEcCtD
Dinoprostone—ABCC4—brain—acquired immunodeficiency syndrome	0.000208	0.00254	CbGeAlD
Dinoprostone—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000208	0.00146	CcSEcCtD
Dinoprostone—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000207	0.00145	CcSEcCtD
Dinoprostone—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000207	0.00145	CcSEcCtD
Dinoprostone—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000207	0.00145	CcSEcCtD
Dinoprostone—SLC22A8—brain—acquired immunodeficiency syndrome	0.000207	0.00252	CbGeAlD
Dinoprostone—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000207	0.00145	CcSEcCtD
Dinoprostone—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000206	0.00145	CcSEcCtD
Dinoprostone—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000206	0.00145	CcSEcCtD
Dinoprostone—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000205	0.00144	CcSEcCtD
Dinoprostone—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000205	0.00144	CcSEcCtD
Dinoprostone—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000205	0.00144	CcSEcCtD
Dinoprostone—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000205	0.00144	CcSEcCtD
Dinoprostone—CYP19A1—lymph node—acquired immunodeficiency syndrome	0.000204	0.00249	CbGeAlD
Dinoprostone—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000203	0.00142	CcSEcCtD
Dinoprostone—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000202	0.00142	CcSEcCtD
Dinoprostone—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000202	0.00142	CcSEcCtD
Dinoprostone—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000202	0.00141	CcSEcCtD
Dinoprostone—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000201	0.00141	CcSEcCtD
Dinoprostone—ABCC4—lymph node—acquired immunodeficiency syndrome	0.000201	0.00246	CbGeAlD
Dinoprostone—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.0002	0.0014	CcSEcCtD
Dinoprostone—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.0002	0.0014	CcSEcCtD
Dinoprostone—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.0002	0.0014	CcSEcCtD
Dinoprostone—CYP1A2—lung—acquired immunodeficiency syndrome	0.0002	0.00244	CbGeAlD
Dinoprostone—Rash—Stavudine—acquired immunodeficiency syndrome	0.0002	0.0014	CcSEcCtD
Dinoprostone—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000199	0.0014	CcSEcCtD
Dinoprostone—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000199	0.00139	CcSEcCtD
Dinoprostone—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000199	0.00139	CcSEcCtD
Dinoprostone—Headache—Stavudine—acquired immunodeficiency syndrome	0.000198	0.00139	CcSEcCtD
Dinoprostone—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000198	0.00139	CcSEcCtD
Dinoprostone—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000198	0.00139	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000198	0.00139	CcSEcCtD
Dinoprostone—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000197	0.00138	CcSEcCtD
Dinoprostone—Rash—Abacavir—acquired immunodeficiency syndrome	0.000197	0.00138	CcSEcCtD
Dinoprostone—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000196	0.00138	CcSEcCtD
Dinoprostone—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000196	0.00138	CcSEcCtD
Dinoprostone—Headache—Abacavir—acquired immunodeficiency syndrome	0.000195	0.00137	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000195	0.00137	CcSEcCtD
Dinoprostone—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000195	0.00136	CcSEcCtD
Dinoprostone—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000193	0.00135	CcSEcCtD
Dinoprostone—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000192	0.00135	CcSEcCtD
Dinoprostone—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000192	0.00135	CcSEcCtD
Dinoprostone—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000191	0.00134	CcSEcCtD
Dinoprostone—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000191	0.00134	CcSEcCtD
Dinoprostone—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000191	0.00134	CcSEcCtD
Dinoprostone—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.00019	0.00133	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000189	0.00133	CcSEcCtD
Dinoprostone—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000189	0.00132	CcSEcCtD
Dinoprostone—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000189	0.00132	CcSEcCtD
Dinoprostone—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000188	0.00132	CcSEcCtD
Dinoprostone—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000188	0.00132	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000188	0.00131	CcSEcCtD
Dinoprostone—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000185	0.0013	CcSEcCtD
Dinoprostone—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000185	0.0013	CcSEcCtD
Dinoprostone—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000184	0.00129	CcSEcCtD
Dinoprostone—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000184	0.00129	CcSEcCtD
Dinoprostone—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.00129	CcSEcCtD
Dinoprostone—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000183	0.00128	CcSEcCtD
Dinoprostone—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000183	0.00128	CcSEcCtD
Dinoprostone—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000183	0.00128	CcSEcCtD
Dinoprostone—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000182	0.00128	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000179	0.00125	CcSEcCtD
Dinoprostone—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000178	0.00125	CcSEcCtD
Dinoprostone—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000176	0.00124	CcSEcCtD
Dinoprostone—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000176	0.00123	CcSEcCtD
Dinoprostone—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000175	0.00123	CcSEcCtD
Dinoprostone—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000175	0.00123	CcSEcCtD
Dinoprostone—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000175	0.00123	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000175	0.00123	CcSEcCtD
Dinoprostone—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000173	0.00122	CcSEcCtD
Dinoprostone—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000173	0.00122	CcSEcCtD
Dinoprostone—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000173	0.00121	CcSEcCtD
Dinoprostone—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000172	0.00121	CcSEcCtD
Dinoprostone—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.00017	0.00119	CcSEcCtD
Dinoprostone—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000169	0.00119	CcSEcCtD
Dinoprostone—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000169	0.00119	CcSEcCtD
Dinoprostone—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000169	0.00119	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000168	0.00118	CcSEcCtD
Dinoprostone—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000168	0.00118	CcSEcCtD
Dinoprostone—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000166	0.00116	CcSEcCtD
Dinoprostone—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000165	0.00116	CcSEcCtD
Dinoprostone—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000163	0.00115	CcSEcCtD
Dinoprostone—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000163	0.00114	CcSEcCtD
Dinoprostone—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000163	0.00114	CcSEcCtD
Dinoprostone—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000163	0.00114	CcSEcCtD
Dinoprostone—Rash—Indinavir—acquired immunodeficiency syndrome	0.000161	0.00113	CcSEcCtD
Dinoprostone—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000161	0.00113	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000161	0.00113	CcSEcCtD
Dinoprostone—Headache—Indinavir—acquired immunodeficiency syndrome	0.00016	0.00112	CcSEcCtD
Dinoprostone—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00016	0.00112	CcSEcCtD
Dinoprostone—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000158	0.00111	CcSEcCtD
Dinoprostone—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000158	0.0011	CcSEcCtD
Dinoprostone—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000155	0.00109	CcSEcCtD
Dinoprostone—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000155	0.00109	CcSEcCtD
Dinoprostone—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000154	0.00108	CcSEcCtD
Dinoprostone—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000153	0.00108	CcSEcCtD
Dinoprostone—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000153	0.00107	CcSEcCtD
Dinoprostone—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000152	0.00107	CcSEcCtD
Dinoprostone—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000152	0.00107	CcSEcCtD
Dinoprostone—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000152	0.00107	CcSEcCtD
Dinoprostone—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000152	0.00106	CcSEcCtD
Dinoprostone—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000151	0.00106	CcSEcCtD
Dinoprostone—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000148	0.00104	CcSEcCtD
Dinoprostone—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000147	0.00103	CcSEcCtD
Dinoprostone—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000146	0.00103	CcSEcCtD
Dinoprostone—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000146	0.00102	CcSEcCtD
Dinoprostone—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000146	0.00102	CcSEcCtD
Dinoprostone—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000145	0.00102	CcSEcCtD
Dinoprostone—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000145	0.00101	CcSEcCtD
Dinoprostone—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000144	0.00101	CcSEcCtD
Dinoprostone—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000141	0.000991	CcSEcCtD
Dinoprostone—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000141	0.000988	CcSEcCtD
Dinoprostone—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.000987	CcSEcCtD
Dinoprostone—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000137	0.000963	CcSEcCtD
Dinoprostone—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000136	0.000954	CcSEcCtD
Dinoprostone—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000136	0.000953	CcSEcCtD
Dinoprostone—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000135	0.000945	CcSEcCtD
Dinoprostone—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000135	0.000944	CcSEcCtD
Dinoprostone—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000134	0.000942	CcSEcCtD
Dinoprostone—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000134	0.000939	CcSEcCtD
Dinoprostone—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000131	0.000917	CcSEcCtD
Dinoprostone—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00013	0.00091	CcSEcCtD
Dinoprostone—Rash—Saquinavir—acquired immunodeficiency syndrome	0.00013	0.00091	CcSEcCtD
Dinoprostone—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.00013	0.000909	CcSEcCtD
Dinoprostone—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000129	0.000904	CcSEcCtD
Dinoprostone—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000127	0.00089	CcSEcCtD
Dinoprostone—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000125	0.000875	CcSEcCtD
Dinoprostone—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.000868	CcSEcCtD
Dinoprostone—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.000867	CcSEcCtD
Dinoprostone—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000123	0.000862	CcSEcCtD
Dinoprostone—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000122	0.000857	CcSEcCtD
Dinoprostone—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000117	0.000818	CcSEcCtD
Dinoprostone—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.75e-05	0.00166	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	8.71e-05	0.00165	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.59e-05	0.00163	CbGpPWpGaD
Dinoprostone—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.57e-05	0.00162	CbGpPWpGaD
Dinoprostone—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.57e-05	0.00162	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.51e-05	0.00161	CbGpPWpGaD
Dinoprostone—PTGER2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	8.47e-05	0.00161	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.41e-05	0.00159	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.41e-05	0.00159	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—TAT—acquired immunodeficiency syndrome	8.31e-05	0.00157	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—IFNA1—acquired immunodeficiency syndrome	8.15e-05	0.00154	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.13e-05	0.00154	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.13e-05	0.00154	CbGpPWpGaD
Dinoprostone—PTGER2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	7.97e-05	0.00151	CbGpPWpGaD
Dinoprostone—PTGER2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	7.97e-05	0.00151	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—APOBEC3G—acquired immunodeficiency syndrome	7.93e-05	0.0015	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7.85e-05	0.00149	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.82e-05	0.00148	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	7.69e-05	0.00146	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	7.51e-05	0.00142	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	7.51e-05	0.00142	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.4e-05	0.0014	CbGpPWpGaD
Dinoprostone—PTGER4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.38e-05	0.0014	CbGpPWpGaD
Dinoprostone—ABCC4—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	7.38e-05	0.0014	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.36e-05	0.00139	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	7.35e-05	0.00139	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	7.35e-05	0.00139	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—TAT—acquired immunodeficiency syndrome	7.28e-05	0.00138	CbGpPWpGaD
Dinoprostone—PTGER4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.27e-05	0.00138	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.24e-05	0.00137	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.24e-05	0.00137	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.23e-05	0.00137	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.23e-05	0.00137	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	7.1e-05	0.00135	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—AGPS—acquired immunodeficiency syndrome	7.07e-05	0.00134	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.79e-05	0.00129	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—CCNT1—acquired immunodeficiency syndrome	6.75e-05	0.00128	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.7e-05	0.00127	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.68e-05	0.00126	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.68e-05	0.00126	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.67e-05	0.00126	CbGpPWpGaD
Dinoprostone—PTGER4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.65e-05	0.00126	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.6e-05	0.00125	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.53e-05	0.00124	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.53e-05	0.00124	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—CSF2—acquired immunodeficiency syndrome	6.38e-05	0.00121	CbGpPWpGaD
Dinoprostone—SLCO2B1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	6.37e-05	0.00121	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	6.29e-05	0.00119	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—AGPS—acquired immunodeficiency syndrome	6.19e-05	0.00117	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.12e-05	0.00116	CbGpPWpGaD
Dinoprostone—PTGER2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.06e-05	0.00115	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	6.04e-05	0.00114	CbGpPWpGaD
Dinoprostone—PTGER2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.97e-05	0.00113	CbGpPWpGaD
Dinoprostone—SLCO2A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.89e-05	0.00112	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.87e-05	0.00111	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.85e-05	0.00111	CbGpPWpGaD
Dinoprostone—SLC22A11—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	5.77e-05	0.00109	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.75e-05	0.00109	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.75e-05	0.00109	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.72e-05	0.00108	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.72e-05	0.00108	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.61e-05	0.00106	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.61e-05	0.00106	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.59e-05	0.00106	CbGpPWpGaD
Dinoprostone—SLCO3A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.59e-05	0.00106	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.53e-05	0.00105	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.51e-05	0.00104	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.5e-05	0.00104	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.5e-05	0.00104	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.5e-05	0.00104	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.49e-05	0.00104	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.49e-05	0.00104	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.49e-05	0.00104	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.49e-05	0.00104	CbGpPWpGaD
Dinoprostone—PTGER2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.46e-05	0.00103	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.42e-05	0.00103	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.38e-05	0.00102	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.38e-05	0.00102	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.38e-05	0.00102	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.38e-05	0.00102	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—TAT—acquired immunodeficiency syndrome	5.34e-05	0.00101	CbGpPWpGaD
Dinoprostone—SLCO4A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.33e-05	0.00101	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.31e-05	0.00101	CbGpPWpGaD
Dinoprostone—SLC22A7—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	5.24e-05	0.000993	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.2e-05	0.000986	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.2e-05	0.000986	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.2e-05	0.000985	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.2e-05	0.000985	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.08e-05	0.000962	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.08e-05	0.000962	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.04e-05	0.000954	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.03e-05	0.000952	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5e-05	0.000948	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.99e-05	0.000946	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.99e-05	0.000946	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.97e-05	0.000941	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.97e-05	0.000941	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.96e-05	0.000939	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.89e-05	0.000926	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.89e-05	0.000926	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.89e-05	0.000926	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.89e-05	0.000926	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	4.87e-05	0.000923	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—IFNA1—acquired immunodeficiency syndrome	4.86e-05	0.000921	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—TAT—acquired immunodeficiency syndrome	4.82e-05	0.000914	CbGpPWpGaD
Dinoprostone—ABCC4—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	4.81e-05	0.000911	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.64e-05	0.000879	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.58e-05	0.000867	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—TAT—acquired immunodeficiency syndrome	4.56e-05	0.000865	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.54e-05	0.000861	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	4.54e-05	0.00086	CbGpPWpGaD
Dinoprostone—SLCO1C1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	4.46e-05	0.000846	CbGpPWpGaD
Dinoprostone—SLC22A8—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	4.4e-05	0.000834	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	4.33e-05	0.000821	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.27e-05	0.00081	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.27e-05	0.00081	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.19e-05	0.000795	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.18e-05	0.000792	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—TAT—acquired immunodeficiency syndrome	4.18e-05	0.000792	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—ALB—acquired immunodeficiency syndrome	4.16e-05	0.000788	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.12e-05	0.00078	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—AGPS—acquired immunodeficiency syndrome	4.1e-05	0.000777	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.09e-05	0.000775	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.09e-05	0.000775	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.03e-05	0.000764	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.03e-05	0.000764	CbGpPWpGaD
Dinoprostone—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	4.01e-05	0.000761	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.96e-05	0.00075	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.94e-05	0.000747	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.94e-05	0.000747	CbGpPWpGaD
Dinoprostone—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.93e-05	0.000745	CbGpPWpGaD
Dinoprostone—SLCO1A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.91e-05	0.000741	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.9e-05	0.000739	CbGpPWpGaD
Dinoprostone—ABCC4—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	3.9e-05	0.000739	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—TAT—acquired immunodeficiency syndrome	3.9e-05	0.000738	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—AGPS—acquired immunodeficiency syndrome	3.88e-05	0.000735	CbGpPWpGaD
Dinoprostone—PTGER4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.84e-05	0.000728	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—CSF2—acquired immunodeficiency syndrome	3.8e-05	0.00072	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.8e-05	0.000719	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.77e-05	0.000714	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.74e-05	0.000709	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.72e-05	0.000704	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.72e-05	0.000704	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.69e-05	0.000699	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.69e-05	0.000699	CbGpPWpGaD
Dinoprostone—SLC22A6—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.67e-05	0.000696	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.66e-05	0.000694	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.66e-05	0.000694	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.57e-05	0.000676	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—AGPS—acquired immunodeficiency syndrome	3.56e-05	0.000674	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—CXCR4—acquired immunodeficiency syndrome	3.54e-05	0.000671	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.49e-05	0.000661	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.48e-05	0.00066	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.47e-05	0.000657	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.42e-05	0.000648	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.39e-05	0.000643	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.39e-05	0.000643	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—IL2—acquired immunodeficiency syndrome	3.37e-05	0.000639	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.35e-05	0.000634	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.35e-05	0.000634	CbGpPWpGaD
Dinoprostone—SLCO1B1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.34e-05	0.000633	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—AGPS—acquired immunodeficiency syndrome	3.31e-05	0.000628	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.25e-05	0.000616	CbGpPWpGaD
Dinoprostone—SLCO2B1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.24e-05	0.000614	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.2e-05	0.000607	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	3.15e-05	0.000598	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	3.15e-05	0.000598	CbGpPWpGaD
Dinoprostone—PTGER2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.15e-05	0.000598	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.14e-05	0.000594	CbGpPWpGaD
Dinoprostone—ABCC5—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.09e-05	0.000586	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.07e-05	0.000582	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.07e-05	0.000582	CbGpPWpGaD
Dinoprostone—SLC22A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.06e-05	0.00058	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3e-05	0.000568	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.95e-05	0.00056	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.95e-05	0.000559	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.95e-05	0.000559	CbGpPWpGaD
Dinoprostone—SLC22A11—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.93e-05	0.000556	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.93e-05	0.000555	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.91e-05	0.000551	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.89e-05	0.000547	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.89e-05	0.000547	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.89e-05	0.000547	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.89e-05	0.000547	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.86e-05	0.000543	CbGpPWpGaD
Dinoprostone—SLC22A1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	2.86e-05	0.000541	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.85e-05	0.00054	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—ALB—acquired immunodeficiency syndrome	2.8e-05	0.00053	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.7e-05	0.000512	CbGpPWpGaD
Dinoprostone—SLC22A7—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.66e-05	0.000504	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.64e-05	0.000501	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—ALB—acquired immunodeficiency syndrome	2.48e-05	0.000469	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—CCR5—acquired immunodeficiency syndrome	2.43e-05	0.00046	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.24e-05	0.000425	CbGpPWpGaD
Dinoprostone—SLC22A8—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.24e-05	0.000424	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.21e-05	0.000419	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.2e-05	0.000416	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.2e-05	0.000416	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.18e-05	0.000412	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.16e-05	0.00041	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.16e-05	0.00041	CbGpPWpGaD
Dinoprostone—ABCC4—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.15e-05	0.000406	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.13e-05	0.000404	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.13e-05	0.000404	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.09e-05	0.000396	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.06e-05	0.00039	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.05e-05	0.000388	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.02e-05	0.000383	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—IL2—acquired immunodeficiency syndrome	2.01e-05	0.000381	CbGpPWpGaD
Dinoprostone—SLCO1A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.99e-05	0.000376	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.98e-05	0.000375	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.98e-05	0.000375	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.98e-05	0.000374	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.93e-05	0.000367	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.93e-05	0.000367	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.89e-05	0.000358	CbGpPWpGaD
Dinoprostone—SLC22A6—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.87e-05	0.000354	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.82e-05	0.000346	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.79e-05	0.000339	CbGpPWpGaD
Dinoprostone—SLCO1B1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.7e-05	0.000322	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.69e-05	0.000321	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.68e-05	0.000319	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.56e-05	0.000296	CbGpPWpGaD
Dinoprostone—SLC22A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.56e-05	0.000295	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.55e-05	0.000294	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.55e-05	0.000294	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—CD4—acquired immunodeficiency syndrome	1.53e-05	0.000289	CbGpPWpGaD
Dinoprostone—SLC22A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.45e-05	0.000275	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—ALB—acquired immunodeficiency syndrome	1.45e-05	0.000275	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—ALB—acquired immunodeficiency syndrome	1.27e-05	0.000241	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.21e-05	0.000229	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.17e-05	0.000221	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.16e-05	0.00022	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.14e-05	0.000217	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.14e-05	0.000217	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.14e-05	0.000215	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.14e-05	0.000215	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.95e-06	0.000188	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—ALB—acquired immunodeficiency syndrome	9.31e-06	0.000176	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.18e-06	0.000174	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—ALB—acquired immunodeficiency syndrome	8.41e-06	0.000159	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—IL6—acquired immunodeficiency syndrome	8.25e-06	0.000156	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—ALB—acquired immunodeficiency syndrome	7.96e-06	0.000151	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—ALB—acquired immunodeficiency syndrome	7.29e-06	0.000138	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.14e-06	0.000135	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.86e-06	0.00013	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—ALB—acquired immunodeficiency syndrome	6.8e-06	0.000129	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.72e-06	0.000127	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.72e-06	0.000127	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	3.18e-06	6.02e-05	CbGpPWpGaD
